Acumen Pharmaceuticals, Inc. (ABOS) News
Filter ABOS News Items
ABOS News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ABOS News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest ABOS News From Around the Web
Below are the latest news stories about ACUMEN PHARMACEUTICALS INC that investors may wish to consider to help them evaluate ABOS as an investment opportunity.
Acumen announces Phase 1 INTERCEPT-AD study publicationAcumen (ABOS) Pharmaceuticals announced that the Journal of Prevention of Alzheimer’s Disease published the results of the Phase 1 INTERCEPT-AD clinical trial demonstrating that sabirnetug was generally well-tolerated with dose- and exposure-dependent target engagement and reduction in amyloid plaques. “The robust data package generated by this Phase 1 study provides important evidence of sabirnetug’s safety profile, further confirms the mechanism of action of sabirnetug and establishes the foun |
Acumen Pharmaceuticals Announces Journal of Prevention of Alzheimer’s Disease Publication of the Company’s Phase 1 INTERCEPT-AD Study, Including Target Engagement, Dosing Regimen and Safety FindingsPhase 1 INTERCEPT-AD data published in Journal of Prevention of Alzheimer’s Disease supports continued development of sabirnetug (ACU193) for treatment of early Alzheimer’s disease (AD) Sabirnetug demonstrated selective, dose-dependent target engagement of amyloid beta oligomers (AβOs), statistically significant amyloid plaque reduction within higher dose cohorts, and low overall levels of ARIA-E Phase 2 ALTITUDE-AD clinical trial of sabirnetug is ongoing with enrollment completion expected 1H 2 |
I-Mab Leads Our Spotlight On 3 US Penny StocksAs the S&P 500 and Nasdaq hit record highs, the U.S. stock market continues its post-election rally with optimism among investors. Amidst this backdrop, penny stocks remain a fascinating segment of the market, often representing smaller or newer companies that can offer unique opportunities for growth. While the term 'penny stocks' might seem outdated, they still hold relevance for those looking to explore investments beyond established giants; here we spotlight three such stocks that stand... |
Acumen Pharmaceuticals to Participate in the 7th Annual Evercore ISI HealthCONx ConferenceNEWTON, Mass., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, announced today that management will participate in a fireside chat at the 7th Annual Evercore ISI HealthCONx Conference on Tuesday, Dec. 3, 2024, at 3:00 p.m. ET. The live webcast may be accessed under the Investors tab on www.acumenpharm. |
Acumen Pharmaceuticals Inc (ABOS) Q3 2024 Earnings Call Highlights: Strong Cash Position and ...Acumen Pharmaceuticals Inc (ABOS) reports a robust cash runway and faster-than-expected enrollment in its ALTITUDE AD Phase 2 study, despite ongoing operational losses. |
Q3 2024 Acumen Pharmaceuticals Inc Earnings CallQ3 2024 Acumen Pharmaceuticals Inc Earnings Call |
Acumen Pharmaceuticals Reports Third Quarter 2024 Financial Results and Business HighlightsExpect ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease, to complete enrollment in the first half of 2025Expect to announce topline results of Phase 1 study to support subcutaneous administration of sabirnetug in the first quarter of 2025Cash, cash equivalents and marketable securities of $258.9 million as of Sept. 30, 2024, expected to support current clinical and operational activities into the first half of 2027Company to host conf |
Acumen Pharmaceuticals to Participate in the Stifel Healthcare ConferenceNEWTON, Mass., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, announced today that management will participate in a fireside chat at the Stifel Healthcare Conference on Monday, Nov. 18, 2024, at 11:30 a.m. ET. The live webcast may be accessed under the Investors tab on www.acumenpharm.com and will be |
Acumen Pharmaceuticals to Participate in the UBS Global Healthcare ConferenceNEWTON, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, announced today that management will participate in a fireside chat at the UBS Global Healthcare Conference on Wednesday, Nov. 13, 2024, at 1:15 p.m. PT (4:15 p.m. ET). The live webcast may be accessed under the Investors tab on www.acumenp |
Acumen Pharmaceuticals Appoints Dr. Amy Schacterle as Chief Regulatory Officer & Head of QualityNEWTON, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), announced today the appointment of Amy Schacterle, Ph.D., as Chief Regulatory Officer & Head of Quality, reporting to Jim Doherty, President & Chief Development Officer at Acumen. “Dr. Schacterle is a highly regarded leader who has su |